论文部分内容阅读
ＡｓｔｒａＺｅｎｅｃａ公司发布了ＥＸＰＲＥＳＳ研究的阳性结果 ,这将支持直接口服凝血酶抑制剂ｘｉｍｅｌａｇａｔｒａｎ〔Ｅｘａｎｔａ ,其活性形式为美拉加群 (ｍｅｌａｇａｔｒａｎ)〕在欧洲市场的应用。该公司对 2 76 4名矫形外科手术患者进行的随机、双盲试验发现 ,ｘ?
AstraZeneca has released positive results from the EXPRESS study, which will support the European market for the direct oral thrombin inhibitor ximelagatran [Exanta, whose active form is melagatran]. The company’s randomized, double-blind trial of 2764 orthopedic patients found that x?